Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
207 studies found for:    "Medulloblastoma"
Show Display Options
Rank Status Study
1 Recruiting A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Condition: Medulloblastoma
Interventions: Radiation: Craniospinal Irradiation with boost to the primary tumor site;   Drug: Cyclophosphamide;   Drug: Cisplatin;   Drug: Vincristine;   Drug: Vismodegib;   Drug: Pemetrexed;   Drug: Gemcitabine;   Other: Aerobic Training;   Other: Neurocognitive Remediation
2 Active, not recruiting Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Conditions: Neuroblastoma;   Medulloblastoma;   Relapse
Intervention: Drug: TPI 287
3 Recruiting Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Conditions: Medulloblastoma;   Neuroectodermal Tumor
Interventions: Biological: TTRNA-xALT;   Biological: TTRNA-DCs
4 Recruiting Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma
Condition: Medulloblastoma
Interventions: Drug: Bevacizumab;   Drug: Thalidomide;   Drug: Celecoxib;   Drug: Fenofibric acid;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Etoposide phosphate;   Drug: Liposomal cytarabine
5 Recruiting A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
Condition: Medulloblastoma
Intervention: Drug: LDE225
6 Not yet recruiting Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Condition: Medulloblastoma
Interventions: Drug: Lomustine;   Drug: Vincristine;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Mesna
7 Withdrawn A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
Conditions: Medulloblastoma, Childhood;   Rhabdomyosarcoma
Intervention: Drug: LY2940680
8 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
9 Recruiting Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma
Conditions: Brain Tumor;   Medulloblastoma;   Pineoblastoma
Intervention: Radiation: proton beam radiation
10 Active, not recruiting Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Conditions: Neuroblastoma;   Medulloblastoma
Intervention: Drug: TPI 287
11 Recruiting Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Conditions: Neuroblastoma;   Medulloblastoma
Interventions: Drug: Nifurtimox;   Drug: Cyclophosphamide;   Drug: Topotecan
12 Active, not recruiting Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma
Condition: Medulloblastoma
Interventions: Radiation: Standard Fractionation Regimen;   Radiation: Hyperfractionated Radiotherapy
13 Recruiting Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas
Condition: Medulloblastoma
Intervention: Drug: carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
14 Active, not recruiting Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Condition: Adult Medulloblastoma
Interventions: Drug: Vismodegib;   Other: Pharmacological Study
15 Recruiting Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma
Conditions: Medulloblastoma, Childhood;   Cerebral Primitive Neuroectodermal Tumor;   Ependymoma
Intervention:
16 Unknown  Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)
Conditions: Metastatic Medulloblastoma;   High Risk Supratentorial PNET;   Metastatic PNET
Interventions: Drug: Carboplatin;   Drug: Vincristine;   Radiation: 24 Gy
17 Recruiting Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
Condition: High-risk Medulloblastoma
Interventions: Drug: Carboplatin + etoposide;   Drug: Thiotepa;   Drug: Cyclophosphamide + Busilvex
18 Active, not recruiting Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
Condition: Recurrent Childhood Medulloblastoma
Interventions: Drug: Vismodegib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
19 Recruiting Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma
Condition: Untreated Childhood Medulloblastoma
Interventions: Drug: vincristine sulfate;   Drug: cyclophosphamide;   Drug: methotrexate;   Drug: etoposide;   Drug: carboplatin;   Other: laboratory biomarker analysis;   Procedure: cognitive assessment
20 Completed GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
Condition: Recurrent Childhood Medulloblastoma
Interventions: Drug: vismodegib;   Other: laboratory biomarker analysis;   Other: pharmacological study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years